Alexander Händel1, Jan Niklas Lüke2, Sebastian Siebelmann2, Jeremy Franklin3, Sigrid Roters2, Mario Matthaei2, Björn O Bachmann2, Claus Cursiefen2,4, Deniz Hos2,4. 1. Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. alexander.haendel@uk-koeln.de. 2. Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Strasse 62, 50924, Cologne, Germany. 3. Institute of Medical Statistics and Bioinformatics, Cologne, Germany. 4. Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50937, Cologne, Germany.
Abstract
PURPOSE: The study aims to compare outcomes after deep anterior lamellar keratoplasty (DALK) and penetrating keratoplasty (PK) in keratoconic eyes with or without previous hydrops. METHODS: Retrospective analysis of 211 eyes who received PK (group 1, n = 74 [history of hydrops: n = 33]) or DALK (group 2, n = 137 [history of hydrops: n = 9]) from 2012 to 2019 at the Department of Ophthalmology, University of Cologne, Germany. Analysis included best spectacle-corrected visual acuity (BSCVA), complications, immune reactions, graft survival and keratometry, and subgroup analyses for subjects with or without previous hydrops. RESULTS: Follow-up was 34.0 ± 23.6 months in group 1 and 30.7 ± 22.5 months in group 2. No significant difference was found in the course of BSCVA between groups 1 and 2 (p = 0.182) and in postoperative BSCVA between eyes with and without previous hydrops, regardless of the surgical method (p = 0.768). Endothelial immune reactions occurred exclusively in group 1 and did not occur more frequently in eyes with previous hydrops (p = 0.377). A higher risk of complications for eyes with previous hydrops was observed (p = 0.022). There was no difference in astigmatism and maximum keratometry (Kmax) preoperatively and postoperatively between eyes with and without history of hydrops. CONCLUSION: The prognosis for visual outcome after keratoplasty including visual acuity, astigmatism, and Kmax for keratoconic eyes with previous hydrops is as good as for keratoconic eyes without previous hydrops, irrespective of the surgical method. However, eyes after hydrops seem to have an increased risk of complications.
PURPOSE: The study aims to compare outcomes after deep anterior lamellar keratoplasty (DALK) and penetrating keratoplasty (PK) in keratoconic eyes with or without previous hydrops. METHODS: Retrospective analysis of 211 eyes who received PK (group 1, n = 74 [history of hydrops: n = 33]) or DALK (group 2, n = 137 [history of hydrops: n = 9]) from 2012 to 2019 at the Department of Ophthalmology, University of Cologne, Germany. Analysis included best spectacle-corrected visual acuity (BSCVA), complications, immune reactions, graft survival and keratometry, and subgroup analyses for subjects with or without previous hydrops. RESULTS: Follow-up was 34.0 ± 23.6 months in group 1 and 30.7 ± 22.5 months in group 2. No significant difference was found in the course of BSCVA between groups 1 and 2 (p = 0.182) and in postoperative BSCVA between eyes with and without previous hydrops, regardless of the surgical method (p = 0.768). Endothelial immune reactions occurred exclusively in group 1 and did not occur more frequently in eyes with previous hydrops (p = 0.377). A higher risk of complications for eyes with previous hydrops was observed (p = 0.022). There was no difference in astigmatism and maximum keratometry (Kmax) preoperatively and postoperatively between eyes with and without history of hydrops. CONCLUSION: The prognosis for visual outcome after keratoplasty including visual acuity, astigmatism, and Kmax for keratoconic eyes with previous hydrops is as good as for keratoconic eyes without previous hydrops, irrespective of the surgical method. However, eyes after hydrops seem to have an increased risk of complications.
Authors: Daphne C Y Han; Jodhbir S Mehta; Yong Ming Por; Hla Myint Htoon; Donald T H Tan Journal: Am J Ophthalmol Date: 2009-07-09 Impact factor: 5.258
Authors: Elias Flockerzi; Philip Maier; Daniel Böhringer; Helga Reinshagen; Friedrich Kruse; Claus Cursiefen; Thomas Reinhard; Gerd Geerling; Necip Torun; Berthold Seitz Journal: Am J Ophthalmol Date: 2018-02-02 Impact factor: 5.258
Authors: William J Reinhart; David C Musch; Deborah S Jacobs; W Barry Lee; Stephen C Kaufman; Roni M Shtein Journal: Ophthalmology Date: 2011-01 Impact factor: 12.079
Authors: Vito Romano; Alfonso Iovieno; Gabriella Parente; Anna Maria Soldani; Luigi Fontana Journal: Am J Ophthalmol Date: 2014-12-06 Impact factor: 5.258
Authors: Mario Matthaei; Heike Sandhaeger; Martin Hermel; Werner Adler; Albert S Jun; Claus Cursiefen; Ludwig M Heindl Journal: Transplantation Date: 2017-06 Impact factor: 4.939